| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 21, 2023 |
| Accession Number: | 0001140361-23-018930 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 21, 2023 |
| Accession Number: | 0001140361-23-018930 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2022 | $19.00 | Buy | Canaccord Genuity |
| 3/10/2022 | $20.00 → $18.00 | Buy | HC Wainwright & Co. |
| 3/10/2022 | $9.00 → $10.00 | Outperform | SVB Leerink |
| 11/23/2021 | $23.00 → $19.00 | Outperform | SVB Leerink |
| 10/4/2021 | $45.00 | Buy | JonesTrading |
| 8/19/2021 | $22.00 | Outperform | SVB Leerink |
| 8/19/2021 | $22.00 | Outperform | Cowen |
| 7/27/2021 | $29.00 | Buy | H.C. Wainwright |
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio. Prior to this, she held senior regional and global leadership roles in AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Roya
DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President Americas. Sheila will lead all aspects of product commercialization for Amryt in the Americas. Sheila has held senior leadership roles across several specialty areas with Novartis, Bristol-Myers Squibb, UCB, and AstraZeneca and has worked and lived in North America and in Europe. Sheila holds an MBA from Concordia University. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Sheila is a very experienced
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
EFFECT - Amryt Pharma plc (0001783010) (Filer)
15F-12B - Amryt Pharma plc (0001783010) (Filer)
EFFECT - Amryt Pharma plc (0001783010) (Filer)
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Immuneering Corporation (NASDAQ:IMRX) Immuneering posted a narrower-than-expected quarterly loss. “2022 was a year of important progress towards our goal of creating impactful
Upgrades According to Citigroup, the prior rating for Pegasystems Inc (NASDAQ:PEGA) was changed from Neutral to Buy. In the third quarter, Pegasystems showed an EPS of $0.34, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.50 and a 52-week-low of $29.05. Pegasystems closed at $35.62 at the end of the last trading period. Mizuho upgraded the previous rating for Oatly Group AB (NASDAQ:OTLY) from Neutral to Buy. Oatly Group earned $0.18 in the third quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $7.98 and a 52-week-low of $1.28. At the end of the last trading period, Oatly Group closed at $2.69. Barclays
Canaccord Genuity resumed coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $19.00
HC Wainwright & Co. reiterated coverage of Amryt Pharma with a rating of Buy and set a new price target of $18.00 from $20.00 previously
SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously
● Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa
Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26
Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1
Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway